Abstract
Low dose-rate brachytherapy (LDR) and hypofractionated external beam radiotherapy (EBRT) are accepted standard treatments in the setting of intermediate-risk (IR) prostate cancer. As yet, none of these options have been tested against one another in a randomized trial. We aim to compare the long term oncologic outcomes of IR prostate cancer patients treated with LDR or EBRT at a single institution.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
